EE03693B1 - Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad - Google Patents

Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad

Info

Publication number
EE03693B1
EE03693B1 EE9800306A EE9800306A EE03693B1 EE 03693 B1 EE03693 B1 EE 03693B1 EE 9800306 A EE9800306 A EE 9800306A EE 9800306 A EE9800306 A EE 9800306A EE 03693 B1 EE03693 B1 EE 03693B1
Authority
EE
Estonia
Prior art keywords
fibroblast activation
activation protein
protein alpha
isolated dimeric
dimeric
Prior art date
Application number
EE9800306A
Other languages
English (en)
Estonian (et)
Other versions
EE9800306A (et
Inventor
Zimmerman Rainer
Edward Park John
Rettig Wolfgang
J. Old Lloyd
Original Assignee
Ludwig Institute For Cancer Research
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute For Cancer Research, Boehringer Ingelheim International Gmbh filed Critical Ludwig Institute For Cancer Research
Publication of EE9800306A publication Critical patent/EE9800306A/xx
Publication of EE03693B1 publication Critical patent/EE03693B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
EE9800306A 1996-03-18 1997-03-12 Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad EE03693B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/619,280 US5767242A (en) 1994-04-20 1996-03-18 Isolated dimeric fibroblast activation protein alpha, and uses thereof
PCT/US1997/004215 WO1997034927A1 (en) 1996-03-18 1997-03-12 Isolated dimeric fibroblast activation protein alpha, and uses thereof

Publications (2)

Publication Number Publication Date
EE9800306A EE9800306A (et) 1999-02-15
EE03693B1 true EE03693B1 (et) 2002-04-15

Family

ID=24481231

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800306A EE03693B1 (et) 1996-03-18 1997-03-12 Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad

Country Status (23)

Country Link
US (2) US5767242A (da)
EP (1) EP0960127B1 (da)
JP (1) JP4102441B2 (da)
KR (1) KR20000064655A (da)
CN (1) CN1214052A (da)
AT (1) ATE449106T1 (da)
AU (1) AU729369B2 (da)
BG (1) BG102781A (da)
BR (1) BR9708100A (da)
CA (1) CA2242342C (da)
CZ (1) CZ299698A3 (da)
DE (1) DE69739665D1 (da)
DK (1) DK0960127T3 (da)
EE (1) EE03693B1 (da)
ES (1) ES2334183T3 (da)
HU (1) HUP0104468A3 (da)
IL (1) IL125124A0 (da)
NO (1) NO984298L (da)
NZ (2) NZ331758A (da)
PL (1) PL328947A1 (da)
SK (1) SK126798A3 (da)
TR (1) TR199801845T2 (da)
WO (1) WO1997034927A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
CA2373643A1 (en) * 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US20030092890A1 (en) * 1999-07-28 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CN1525868A (zh) * 2001-07-09 2004-09-01 埃弗顿有限公司 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状
CA2484551A1 (en) 2002-04-30 2003-11-13 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
JP2006507352A (ja) * 2002-07-09 2006-03-02 ポイント セラピューティクス， インコーポレイテッド イソロイシンのボロプロリン化合物に関する方法および組成物
US20080057491A1 (en) * 2003-02-07 2008-03-06 Mckee Patrick A Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US7309774B2 (en) * 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
EP1784645A2 (en) * 2004-07-29 2007-05-16 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with fibroblast activation protein
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
EP1812458A2 (en) * 2004-10-27 2007-08-01 Wen-Tien Chen Methods and compositions for seprase inactivation
HUE028818T2 (en) 2004-11-24 2017-01-30 Techlab Inc Tool and method for detecting analytes
WO2007111657A2 (en) 2005-12-14 2007-10-04 Ludwig Institute For Cancer Research Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
ES2393372T3 (es) * 2006-06-21 2012-12-20 The Scripps Research Institute Composición de ADN contra el antígeno tumoral estromal FAP y métodos de utlización de la misma
US8513187B2 (en) 2009-02-27 2013-08-20 Trustees Of Tufts College Soft protease inhibitors, and pro-soft forms thereof
WO2014102312A2 (en) 2012-12-28 2014-07-03 Life Sciences Research Partners Vzw Minimally toxic prodrugs
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015192123A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
CN105859866B (zh) * 2016-05-27 2019-08-13 郑州大学 Fap来源的抗肿瘤ctl表位肽p265及其应用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN111050789A (zh) 2017-06-15 2020-04-21 癌症进展有限公司 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
US5587299A (en) * 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof

Also Published As

Publication number Publication date
NO984298D0 (no) 1998-09-17
EP0960127A1 (en) 1999-12-01
PL328947A1 (en) 1999-03-01
AU729369B2 (en) 2001-02-01
DK0960127T3 (da) 2010-03-29
CN1214052A (zh) 1999-04-14
NO984298L (no) 1998-09-17
ES2334183T3 (es) 2010-03-05
JP2000507100A (ja) 2000-06-13
EP0960127A4 (en) 2004-09-08
HUP0104468A3 (en) 2004-10-28
TR199801845T2 (xx) 1998-12-21
BG102781A (en) 1999-09-30
CA2242342A1 (en) 1997-09-25
NZ331758A (en) 2000-01-28
WO1997034927A1 (en) 1997-09-25
HUP0104468A2 (hu) 2002-04-29
CA2242342C (en) 2013-05-14
ATE449106T1 (de) 2009-12-15
US5767242A (en) 1998-06-16
US5965373A (en) 1999-10-12
EP0960127B1 (en) 2009-11-18
NZ335543A (en) 2001-03-30
BR9708100A (pt) 2000-01-04
KR20000064655A (ko) 2000-11-06
AU2330297A (en) 1997-10-10
EE9800306A (et) 1999-02-15
SK126798A3 (en) 1999-05-07
JP4102441B2 (ja) 2008-06-18
DE69739665D1 (de) 2009-12-31
CZ299698A3 (cs) 1999-01-13
IL125124A0 (en) 1999-01-26

Similar Documents

Publication Publication Date Title
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ES2195970T3 (es) L-ribavirina y usos de la misma.
NO2013009I1 (no) Alipogen tiparvovec
TR200100056T2 (tr) Nörotrofik faktörler
DE69534778D1 (en) Cathepsin-02-protease
AR016981A2 (es) Polipeptidos sinteticos
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
TR200002101T2 (tr) Dondurulmuş gıda ürünü.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
DK1012175T3 (da) Peptid med affinitet til koagulationsfaktor VIII
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
DK0942992T3 (da) O-fucosyltransferase
PE20399A1 (es) Muteina ob
ATE313627T1 (de) Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen
BG102937A (en) Zona pelucida proteins as contraceptives
DZ2803A1 (fr) Polypeptide de la protéine c humaine.
SE9604439D0 (sv) New receptor
ZA978233B (en) The use of protein as anti-retroviral agents.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
DE69636231D1 (de) Menschliche chemokin-polypeptide.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

MM4A Lapsed by not paying the annual fees

Effective date: 20040312